PMC:4134656 / 29281-30089 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/4134656","sourcedb":"PMC","sourceid":"4134656","source_url":"https://www.ncbi.nlm.nih.gov/pmc/4134656","text":"Topical propranolol 1% ointment has been used successfully in the treatment of superficial IHs, especially as an adjuvant therapy during the wait-and-watch period. Kunzi-Rapp et al. in their series of 45 cases of superficial haemangiomas, used propranolol 1% ointment locally twice daily.[54] Of the 65 haemangiomas treated, 59% showed regression and 26% had cessation of growth. In 15% of the cases, no response was seen. Concomitant use of propranolol ointment with pulsed dye laser (PDL) in two of their cases of ulcerated haemangioma led to healing of ulcers in 3 and 6 weeks, respectively. In a retrospective chart review by Xu et al., 16 (57%) out of 28 haemangiomas demonstrated good response, 9 (33%) showed partial response and 3 (10%) had no response.[55] No side-effects have been reported so far.","tracks":[{"project":"2_test","denotations":[{"id":"25136206-22516113-58659619","span":{"begin":289,"end":291},"obj":"22516113"},{"id":"25136206-22141326-58659620","span":{"begin":762,"end":764},"obj":"22141326"}],"attributes":[{"subj":"25136206-22516113-58659619","pred":"source","obj":"2_test"},{"subj":"25136206-22141326-58659620","pred":"source","obj":"2_test"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"2_test","color":"#93ecea","default":true}]}]}}